Background Coeliac disease, an autoimmune disorder affecting approximately 1% of the global population, is typically diagnosed on a duodenal biopsy. However, inter-pathologist agreement on coeliac disease diagnosis is only around 80%. Existing machine learning solutions designed to improve coeliac disease diagnosis often lack interpretability, which is essential for building trust and enabling widespread clinical adoption.

Objective To develop an interpretable AI model capable of segmenting key histological structures in duodenal biopsies, generating explainable segmentation masks, estimating intraepithelial lymphocyte (IEL)-to-enterocyte and villus-to-crypt ratios, and diagnosing coeliac disease.

Design Semantic segmentation models were trained to identify villi, crypts, IELs, and enterocytes using 49 annotated 2048×2048 patches at 40x magnification. IEL-to-enterocyte and villus-to-crypt ratios were calculated from segmentation masks, and a logistic regression model was trained on 172 images to diagnose coeliac disease based on these ratios. Evaluation was performed on an independent test set of 613 duodenal biopsy scans from a separate NHS Trust.

Results The villus-crypt segmentation model achieved a mean PR AUC of 80.5%, while the IEL-enterocyte model reached a PR AUC of 82%. The diagnostic model classified WSIs with 96% accuracy, 86% positive predictive value, and 98% negative predictive value on the independent test set.

Conclusions Our interpretable AI models accurately segmented key histological structures and diagnosed coeliac disease in unseen WSIs, demonstrating strong generalization performance. These models provide pathologists with reliable IEL-to-enterocyte and villus-to-crypt ratio estimates, enhancing diagnostic accuracy. Interpretable AI solutions like ours are essential for fostering trust among healthcare professionals and patients, complementing existing black-box methodologies.

What is already known on this topic Pathologist concordance in diagnosing coeliac disease from duodenal biopsies is consistently reported to be below 80%, highlighting diagnostic variability and the need for improved methods. Several recent studies have leveraged artificial intelligence (AI) to enhance coeliac disease diagnosis. However, most of these models operate as “black boxes,” offering limited interpretability and transparency. The lack of explainability in AI-driven diagnostic tools prevents widespread adoption by healthcare professionals and reduces patient trust.

What this study adds This study presents an interpretable semantic segmentation algorithm capable of detecting the four key histological structures essential for diagnosing coeliac disease: crypts, villi, intraepithelial lymphocytes (IELs), and enterocytes. The model accurately estimates the IEL-to-enterocyte ratio and the villus-to-crypt ratio, the latter being an indicator of villous atrophy and crypt hyperplasia, thereby providing objective, reproducible metrics for diagnosis. The segmentation outputs allow for transparent, explainable decision-making, supporting pathologists in coeliac disease diagnosis with improved accuracy and confidence.

This study presents an AI model that automates the estimation of the IEL-to-enterocyte ratio—a labour-intensive task currently performed manually by pathologists in limited biopsy regions. By minimising diagnostic variability and alleviating time constraints for pathologists, the model provides an efficient and practical solution to streamline the diagnostic workflow. Tested on an independent dataset from a previously unseen source, the model demonstrates explainability and generalizability, enhancing trust and encouraging adoption in routine clinical practice. Furthermore, this approach could set a new standard for AI-assisted duodenal biopsy evaluation, paving the way for the development of interpretable AI tools in pathology to address the critical challenges of limited pathologist availability and diagnostic inconsistencies.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The following authors are shareholders in Lyzeum Ltd: F.J., J.D., M.J. A., and E.S.

This work has been supported by Coeliac UK, Innovate UK (grant INOV03 19 to ES), NIHR (grant NIHR205502) and the Cambridge Centre for Data Driven Discovery (C2D3).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study involves human participants and was approved. All slide scans (and accompanying fully anonymised patient data) were obtained with full ethical approval (IRAS: 162057; PI: Dr E Soilleux). Organisation: South Central - Oxford A (formally known as Oxfordshire Research Ethics Committee A).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The datasets of WSIs analysed during this current study have not publicly available due to the large size of the WSIs and no patient agreements.